reflect updat definit core financi measur exclud
intang asset amort charg impair except
is-rel intang
sale beat forecast solid trend ep big beat driven tax rate incom
core ep guidanc bit better expect still y/i due patent expiri
spend new product launch
core ep estim newli issu guidanc
call core ep cer fx impact expect minim last
publish ep estim increas
revenu sale extern revenu
forecast product beat estim includ crestor pulmicort
symbicort onglyza brilinta tagrisso imfinzi
forxiga bydureon combin ahead forecast
key product forecast nexium sale guidanc sale
includ extern revenu low singl digit increas cer fx impact
expect low single-digit posit last publish revenu estim
review
gpm estim
estim sg forecast op incom
forecast net financi expens
estim tax rate one-tim adjust well
estim ad ep share count line guidanc
gpm vs last publish declin low single-
digit declin stabl vs sg increas low mid singl digit vs
support new launch tax rate rang vs
fasenra ph data/fil copd tagrisso japan
approv egfr nsclc imfinzi approv unresect stage nsclc
nsclc ph ii/iii data sschn kestrel eagl file
os data nsclc mystic file ph data/fil
nsclc neptun imfinzi lynparza ph data mediola basket
studi lynparza ph data/fil brcam ovarian cancer eu
approv ovarian cancer eu file japan approv
brca mbc ph data pancreat cancer bydureon autoinjector eu approv
farxiga cv outcom declar data close tripl file copd
selumetinib ph data/fil thyroid cancer bevespi eu approv copd
roxadustat ph data anemia file anifrolumab data sle
 /eu approv manufactur issu resolv
pleas see page report import disclosur
azn promis pipelin eventu particip mani larg high
growth market offset promis outlook challeng data sever
key pipelin asset await diabet respiratori franchis outlook unclear ep
prospect murki next coupl year astra practic book revenu
incom product sold whether interest retain make azn ep
directli compar peer azn clearli improv await greater clariti
lung cancer
imfinzi tremelimumab phase data
lung cancer
lynparza data/fil ovarian
cancer eu approv brcam ovarian
 s/ eu approv hyperkalemia
brilinta unabl sustain share gain
astrazeneca biopharmaceut compani domicil group
acquir medimmun biolog vaccin busi base key product
area cardiovascular respiratori oncolog
cowen compani
cowen compani
reportedour estimatedifferenceproduct exceed cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl crestor brilinta
success pipelin product success deal patent litig patent
expir pressur uncertainti strateg direct could includ
outlook dividend
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock astrazeneca plc adr secur
author report member author household long posit equiti secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
